Identification of androgen-regulated genes in human prostate

Vaarala,Markku  H.; Hirvikoski,Pasi; Kauppila,Saila; Paavonen,Timo  K.

doi:10.3892/mmr.2012.956

Identification of androgen-regulated genes in human prostate

Authors:
- Markku H. Vaarala
- Pasi Hirvikoski
- Saila Kauppila
- Timo K. Paavonen
View Affiliations

Affiliations: Department of Surgery, Oulu University Hospital, FIN-90029 Oulu, Finland, Department of Pathology, Oulu University Hospital and Länsi-Pohja Central Hospital, FIN-90029 Oulu, Finland , Department of Pathology, University of Oulu, FIN-90014 Oulu, Finland, Department of Pathology, University of Tampere and Tampere University Hospital, School of Medicine, FIN-33014 Tampere, Finland
Published online on: June 19, 2012 https://doi.org/10.3892/mmr.2012.956
Pages: 466-472
Copyright: © Vaarala et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Androgens are essential for the development of the prostate and prostate cancer. We examined androgen-regulated gene expression in the human prostate. Samples from benign and malignant prostate tissue and samples containing prostate tissue obtained from prostate cancer patients three days after surgical castration were further processed as probes for a GeneChip array. The comparison of gene expression profiles in castrated samples and in benign or malignant prostate tissue samples revealed androgen-regulated genes. We further evaluated the genes which were differentially expressed in benign and malignant prostate samples. The androgen-regulated expression of dual specificity phosphatase 1 (DUSP1) was confirmed in the LNCaP prostate cancer cell line, as the expression of DUSP1 increased with androgen treatment over the course of time. The expression of the genes CRISP3, PCA3, OR51E2, HOXC6, AGR3, AMACR and SLC14A1 was affected by castration in addition to differential expression in the benign and malignant prostate. These sample results require further investigation for the role of AGR3 and SLC14A1 in prostate cancer as these associations have not been reported previously.

View Figures

View References

1	Bennett NC, Gardiner RA, Hooper JD, Johnson DW and Gobe GC: Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol. 42:813–827. 2010. View Article : Google Scholar : PubMed/NCBI
2	Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, et al: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 164:217–227. 2004. View Article : Google Scholar
3	Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, et al: Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res. 11:6823–6834. 2005. View Article : Google Scholar : PubMed/NCBI
4	Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67:5033–5041. 2007. View Article : Google Scholar
5	Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD and Nelson PS: Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res. 70:1286–1295. 2010. View Article : Google Scholar : PubMed/NCBI
6	Majalahti-Palviainen T, Hirvinen M, Tervonen V, Ilves M, Ruskoaho H and Vuolteenaho O: Gene structure of a new cardiac peptide hormone: a model for heart-specific gene expression. Endocrinology. 141:731–740. 2000.PubMed/NCBI
7	Kamburov A, Wierling C, Lehrach H and Herwig R: ConsensusPathDB--a database for integrating human functional interaction networks. Nucleic Acids Res. 37:D623–D628. 2009. View Article : Google Scholar : PubMed/NCBI
8	Edgar R, Domrachev M and Lash AE: Gene expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
9	Dahlman A, Edsjö A, Halldén C, Persson JL, Fine SW, Lilja H, Gerald W and Bjartell A: Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis. 13:369–375. 2010. View Article : Google Scholar : PubMed/NCBI
10	Szabo Z, Hamalainen J, Loikkanen I, Moilanen AM, Hirvikoski P, Vaisanen T, Paavonen TK and Vaarala MH: Sorbitol dehydrogenase expression is regulated by androgens in the human prostate. Oncol Rep. 23:1233–1239. 2010.PubMed/NCBI
11	Bjartell A, Johansson R, Bjork T, Gadaleanu V, Lundwall A, Lilja H, Kjeldsen L and Udby L: Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate. 66:591–603. 2006. View Article : Google Scholar : PubMed/NCBI
12	Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, et al: PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci USA. 97:12216–12221. 2000. View Article : Google Scholar : PubMed/NCBI
13	de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW and Schalken JA: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62:2695–2698. 2002.
14	Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, et al: PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res. 60:6568–6572. 2000.PubMed/NCBI
15	Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr and Kristal AR: Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 18:2807–2813. 2009. View Article : Google Scholar : PubMed/NCBI
16	Murtola TJ, Tammela TL, Lahtela J and Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 16:2226–2232. 2007. View Article : Google Scholar : PubMed/NCBI
17	Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES and Wasan KM: Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate. 70:390–400. 2010.
18	Mol AJ, Geldof AA, Meijer GA, van der Poel HG and van Moorselaar RJ: New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration. J Cancer Res Clin Oncol. 133:687–695. 2007. View Article : Google Scholar : PubMed/NCBI
19	Leav I, Galluzzi CM, Ziar J, Stork PJ, Ho SM and Loda M: Mitogen-activated protein kinase and mitogen-activated kinase phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest. 75:361–370. 1996.PubMed/NCBI
20	Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ and Loda M: Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest. 76:37–51. 1997.PubMed/NCBI
21	Rauhala HE, Porkka KP, Tolonen TT, Martikainen PM, Tammela TL and Visakorpi T: Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer. 117:738–745. 2005. View Article : Google Scholar : PubMed/NCBI
22	King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, et al: The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol. 35:904–912. 2011. View Article : Google Scholar : PubMed/NCBI
23	Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JA, Daviet L, Legrain P, Parekh R, Harris AL and Terrett JA: hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer. 88:579–585. 2003. View Article : Google Scholar : PubMed/NCBI
24	Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, Witjes JA, Grotenhuis AJ, Verhaegh GW, Hulsbergen-van de Kaa CA, Besenbacher S, et al: European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet. 20:4268–4281. 2011. View Article : Google Scholar : PubMed/NCBI
25	Henttu P and Vihko P: Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. Ann Med. 26:157–164. 1994. View Article : Google Scholar : PubMed/NCBI
26	Young CY, Andrews PE and Tindall DJ: Expression and androgenic regulation of human prostate-specific kallikreins. J Androl. 16:97–99. 1995.PubMed/NCBI